Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-04-08
1999-07-20
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514339, 546256, 5462771, C07D40114, C07D20946, A61K 3140
Patent
active
059256559
ABSTRACT:
This invention relates to certain novel isoindolone compounds and derivatives thereof, their synthesis, and their use as .alpha.v.beta.3 receptor antagonists. The .alpha.v.beta.3 receptor antagonist compounds of this invention are useful for inhibiting bone resorption, treating and preventing osteoporosis and cancer, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation and tumor growth.
REFERENCES:
patent: 4505911 (1985-03-01), Dolak et al.
patent: 5416099 (1995-05-01), Hartman et al.
patent: 5491232 (1996-02-01), Patsch et al.
Omenn, Cancer Prevention, Cecil Textbook of Medicine, 20th Edition, vol. 1, pp. 1008-1010, 1996.
Duggan Mark E.
Hartman George D.
Hoffman William F.
Durette Philippe L.
Merck & Co. , Inc.
Rao Deepak R.
Raymond Richard L.
Sabatelli Anthony D.
LandOfFree
.alpha..sub.v .beta..sub.3 antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with .alpha..sub.v .beta..sub.3 antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and .alpha..sub.v .beta..sub.3 antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1322175